Changes in Beneficial Ownership · 4
SenesTech, Inc.
SNESNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-15
- Issuer
- SenesTech, Inc.
- Issuer CIK
- 0001680378
- Trading symbol
- SNES
Reporting owner 1
- Name
- GLENBROOK CAPITAL MANAGEMENT
- Reporting owner CIK
- 0001273782
- Relationship
- 10% owner
- Address
- 2207, SUITE B, BELLANCA ST., MINDEN, NV, 89423
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value per share ("Common Stock") | 2026-10-15 | P · Form 4 | 426,000 | A | 0.7679[F1] | 1,505,294 | I | See footnote[F2] |
| Common Stock | 2026-10-16 | P · Form 4 | 181,252 | A | 0.6289[F3] | 1,686,546 | I | See footnote[F2] |
| Common Stock | 2026-10-19 | P · Form 4 | 376,552 | A | 0.7036[F4] | 2,063,098 | I | See footnote[F2] |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- I
- Indirect
Footnotes
- F1
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6331 to $0.8906, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.↩ 1
- F2
- The securities to which this filing relates are held directly by certain accounts for which Glenbrook Capital Management (the "Reporting Person") serves as the investment manager. The Reporting Person disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.↩ 1↩ 2↩ 3
- F3
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5629 to $0.6582, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.↩ 1
- F4
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $ $0.6335 to $0.7482, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.↩ 1
Signature 1
- Signed
- Glenbrook Capital Management, By: /s/ Robert W. Lishman, Director
- Date
- 2026-10-19
Company context
SenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The company’s groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech’s mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.
Current securities
Historical securities (1)
Recent company filings
- 4 filingOct 30, 2026
- SCHEDULE 13D/A - filed by GLENBROOK CAPITAL MANAGEMENT regarding SenesTech, Inc.Oct 30, 2026
- 4 filingOct 22, 2026
- SCHEDULE 13D/A - filed by GLENBROOK CAPITAL MANAGEMENT regarding SenesTech, Inc.Oct 22, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD DisclosureOct 22, 2026